Diagnostics and biomarker development: priming the pipeline

[1]  S. Fadem,et al.  One year later. , 2017, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[2]  M. Gold.  Cost-effectiveness in health and medicine , 2016 .

[3]  Mark A. Rothstein,et al.  Genetic Exceptionalism and Legislative Pragmatism , 2007, Journal of Law, Medicine & Ethics.

[4]  M. Ackerman,et al.  Cost-effectiveness analysis of genetic testing for familial long QT syndrome in symptomatic index cases. , 2005, Heart rhythm.

[5]  M. Rothstein,et al.  Genetic Exceptionalism & Legislative Pragmatism , 2005, The Hastings Center report.

[6]  Kathryn A. Phillips,et al.  Measuring the value of pharmacogenomics , 2005, Nature Reviews Drug Discovery.

[7]  M. Wadman.  Drug safety special: The safety catch , 2005, Nature.

[8]  Kathryn A Phillips,et al.  A systematic review of cost-effectiveness analyses of pharmacogenomic interventions. , 2004, Pharmacogenomics.

[9]  I Zineh,et al.  Availability of pharmacogenomics-based prescribing information in drug package inserts for currently approved drugs , 2004, The Pharmacogenomics Journal.

[10]  L. Demers,et al.  Pharmacogenomics and pharmacogenetics: future role of molecular diagnostics in the clinical diagnostic laboratory. , 2004, Clinical chemistry.

[11]  A. Issa.  The regulation of pharmacogenomics-based drugs and policy making. , 2004, Current topics in medicinal chemistry.

[12]  Hannah Hoag,et al.  Testing new ground , 2004, Nature.

[13]  G. Tsongalis.  A reality check for molecular diagnostics in clinical practice. , 2003, Pharmacogenomics.

[14]  D. Melzer,et al.  Regulatory options for pharmacogenetics. , 2003, Pharmacogenomics.

[15]  Kathryn A Phillips,et al.  An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics. , 2003, Pharmacogenomics.

[16]  P. Danzon,et al.  Productivity in Pharmaceutical Biotechnology R&D: The Role of Experience and Alliances , 2003, Journal of health economics.

[17]  P. Manasco,et al.  Drug Development Strategies , 2003 .

[18]  D. Feigal,et al.  Drug Development, Regulation, and Genetically Guided Therapy , 2003 .

[19]  K. Lindpaintner.  Pharmacogenetics and the future of medical practice , 2003, Journal of Molecular Medicine.

[20]  D. Gurwitz,et al.  Education: Teaching pharmacogenomics to prepare future physicians and researchers for personalized medicine. , 2003, Trends in pharmacological sciences.

[21]  J. Kahn,et al.  Pharmacogenetic challenges for the health care system. , 2002, Health affairs.

[22]  A. Califano,et al.  Pharmacogenetics: Ethical Issues and Policy Options , 2002, Kennedy Institute of Ethics journal.

[23]  Jason E. Stewart,et al.  Minimum information about a microarray experiment (MIAME)—toward standards for microarray data , 2001, Nature Genetics.

[24]  S. Gutman.  The role of Food and Drug Administration regulation of in vitro diagnostic devices--applications to genetics testing. , 1999, Clinical chemistry.

[25]  Lars Brandel.  Safety catch , 2006, Nature.

[26]  J. Wechsler.  Drug development linked more closely to diagnostics , 2004 .

[27]  Scott D Ramsey,et al.  Clinical use of medical devices in the 'Bermuda Triangle'. , 2004, Health affairs.

[28]  F. Collins,et al.  Pharmacogenomics : social, ethical, and clinical dimensions , 2003 .

[29]  N M Davis,et al.  The critical path. , 1982, Hospital pharmacy.